September 24, 2015
J-Codes, the billing codes used for medical therapies and procedures, could impact how well physicians and health care systems can monitor patient responses to biological medicines as more biosimilars enter the U.S. market.
September 23, 2015
The Centers for Disease Control and Prevention has drafted new guidelines on prescribing opioids for chronic pain—and they could be bad news for patients living with pain.
September 22, 2015
For patients, the immense value of a life-changing medication can be difficult to quantify.
September 21, 2015
The Senate Subcommittee on Primary Health and Retirement Security’s September 17 hearing featuring FDA Director Janet Woodcock, MD, resulted in a packed hearing room—and hopes that FDA guidance on unresolved policy issues affecting biosimilars will materialize sooner rather than later.
September 17, 2015
This month advocates, patients and their families reflect on the toll cancer takes, the progress that new treatment options offer and the obstacles that too many patients still face.
September 15, 2015
Hepatitis C patients have a one in four chance of receiving curative treatment on their initial request, a new Yale University School of Medicine study reveals.
September 11, 2015
Biosimilar cost savings have arrived. But they are proving much less robust than proponents had hoped.
September 10, 2015
Five years after the federal government approved an abbreviated regulatory pathway for biosimilars, physicians and patients still lack clarity on a number of core issues.
September 8, 2015
Innovative pill formulations offer a new option for battling prescription opioid abuse, explains a recently released video from the Alliance for Patient Access.
September 3, 2015
Fragile preemies and newborns may face the risk of respiratory syncytial virus (RSV) from the most well-meaning source—their parents.
